Shionogi applies to trademark its COVID-19 treatment
By Kim, Jin-Gu | translator Alice Kang
22.05.17 06:18:49
가나다라
0
Trademark application review for 6 brands including Xocova·Zocovati in their final stages in Korea
Ildong “plans to apply for emergency use authorization in Korea if the drug receives conditional approval in Japan”
With the domestic trademark application for the COVID-19 treatment that is being jointly developed by Shionogi Pharma and Ildong Pharmaceutical nearing completion, Shionogi Pharma and Ildong Pharmaceutical are speeding up preparations to commercialize its drug in Korea in the second half of this year.
▲ Shionogi submitted a trademark application for XOCOVA
According to the Korean Intellectual Property Office on the 7th, Shionogi Pharma recently submitted an application for 6 trademarks including ‘Xocava.’ The trademarks were registered for ▲ antiviral drugs ▲ drugs for human use ▲ drugs for medical use ▲ animal drugs, etc.In addition to ‘Xocova,’ Shionogi submitted trademark applications for ‘Zocovea,’ ‘Zocovaty,’ ‘Xovished,’ �
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)